Impact of Proposed U.S. Tariffs on India's Pharmaceutical Sector and Strategies for Resilience
The U.S. has proposed a 100% tariff on branded and patented pharmaceutical imports, posing a significant challenge to India, the 'pharmacy of the world.' India's $50 billion pharma sector contributes 1.72% to its GDP and supplies 40% of U.S. generics. To mitigate risks, India has implemented GST rationalization for drugs (dropping from 12% to 5%) and is promoting domestic manufacturing through PLI schemes. The API sector is projected to grow significantly, reaching ₹1.82 trillion by 2030. Diversification into African and Southeast Asian markets is also being prioritized to offset tariff risks.
Key Points
- India supplies 40% of U.S. generic drugs, saving the U.S. healthcare system approximately $219 billion in 2022.
- Proposed 100% U.S. tariffs could impact India's $50 billion pharmaceutical sector, which contributes 1.72% to national GDP.
- GST on many drugs and medicines was reduced from 12% to 5% effective September 22, 2025, to provide domestic ballast.
- The Production Linked Incentive (PLI) scheme aims to reclaim 20% domestic production in the Active Pharmaceutical Ingredients (API) sector.
Exam Facts
- India's pharmaceutical sector contributes approximately 1.72% to the national GDP.
- The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has opened over 16,912 Kendras as of June 2025.
- India's API sector is projected to grow to ₹1.82 trillion by 2030.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.